360 related articles for article (PubMed ID: 33995085)
1. AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?
Martorana F; Motta G; Pavone G; Motta L; Stella S; Vitale SR; Manzella L; Vigneri P
Front Pharmacol; 2021; 12():662232. PubMed ID: 33995085
[TBL] [Abstract][Full Text] [Related]
2. "The emerging role of capivasertib in breast cancer".
Andrikopoulou A; Chatzinikolaou S; Panourgias E; Kaparelou M; Liontos M; Dimopoulos MA; Zagouri F
Breast; 2022 Jun; 63():157-167. PubMed ID: 35398754
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models.
Cocco S; Leone A; Roca MS; Lombardi R; Piezzo M; Caputo R; Ciardiello C; Costantini S; Bruzzese F; Sisalli MJ; Budillon A; De Laurentiis M
J Transl Med; 2022 Jun; 20(1):290. PubMed ID: 35761360
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis.
Han Y; Wang J; Wang Z; Xu B
Curr Probl Cancer; 2020 Dec; 44(6):100606. PubMed ID: 32446638
[TBL] [Abstract][Full Text] [Related]
5. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
Costa RLB; Han HS; Gradishar WJ
Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
[TBL] [Abstract][Full Text] [Related]
6. Capivasertib: A Novel AKT Inhibitor Approved for Hormone-Receptor-Positive, HER-2-Negative Metastatic Breast Cancer.
Luboff AJ; DeRemer DL
Ann Pharmacother; 2024 Apr; ():10600280241241531. PubMed ID: 38566315
[TBL] [Abstract][Full Text] [Related]
7. Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer.
Alves CL; Ditzel HJ
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901954
[TBL] [Abstract][Full Text] [Related]
8. PTEN-PI3K pathway alterations in advanced prostate cancer and clinical implications.
Choudhury AD
Prostate; 2022 Aug; 82 Suppl 1():S60-S72. PubMed ID: 35657152
[TBL] [Abstract][Full Text] [Related]
9. Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling.
Grunt TW; Mariani GL
Curr Cancer Drug Targets; 2013 Feb; 13(2):188-204. PubMed ID: 23215720
[TBL] [Abstract][Full Text] [Related]
10. Clinical Development of AKT Inhibitors and Associated Predictive Biomarkers to Guide Patient Treatment in Cancer Medicine.
Coleman N; Moyers JT; Harbery A; Vivanco I; Yap TA
Pharmgenomics Pers Med; 2021; 14():1517-1535. PubMed ID: 34858045
[TBL] [Abstract][Full Text] [Related]
11. Resistance to Targeted Inhibitors of the PI3K/AKT/mTOR Pathway in Advanced Oestrogen-Receptor-Positive Breast Cancer.
Browne IM; Okines AFC
Cancers (Basel); 2024 Jun; 16(12):. PubMed ID: 38927964
[TBL] [Abstract][Full Text] [Related]
12. Current status and future perspectives of PI3K and mTOR inhibitor as anticancer drugs in breast cancer.
Zhang X; Li XR; Zhang J
Curr Cancer Drug Targets; 2013 Feb; 13(2):175-87. PubMed ID: 23215724
[TBL] [Abstract][Full Text] [Related]
13. PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials.
Dey N; De P; Leyland-Jones B
Pharmacol Ther; 2017 Jul; 175():91-106. PubMed ID: 28216025
[TBL] [Abstract][Full Text] [Related]
14. Overview of the Development and Use of Akt Inhibitors in Prostate Cancer.
Gasmi A; Roubaud G; Dariane C; Barret E; Beauval JB; Brureau L; Créhange G; Fiard G; Fromont G; Gauthé M; Ruffion A; Renard-Penna R; Sargos P; Rouprêt M; Ploussard G; Mathieu R
J Clin Med; 2021 Dec; 11(1):. PubMed ID: 35011901
[TBL] [Abstract][Full Text] [Related]
15. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer.
Gonzalez-Angulo AM; Blumenschein GR
Cancer Treat Rev; 2013 Jun; 39(4):313-20. PubMed ID: 23218708
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of PI3K/Akt/mTOR inhibitors combined with trastuzumab therapy for HER2-positive breast cancer: a meta-analysis.
Peng DS; Huang BQ; Ning HT; Zhu XZ
Eur Rev Med Pharmacol Sci; 2022 Oct; 26(20):7667-7678. PubMed ID: 36314338
[TBL] [Abstract][Full Text] [Related]
17. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
18. Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer - A comprehensive review from chemotherapy to immunotherapy.
Jabbarzadeh Kaboli P; Salimian F; Aghapour S; Xiang S; Zhao Q; Li M; Wu X; Du F; Zhao Y; Shen J; Cho CH; Xiao Z
Pharmacol Res; 2020 Jun; 156():104806. PubMed ID: 32294525
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulatory Properties of PI3K/AKT/mTOR and MAPK/MEK/ERK Inhibition Augment Response to Immune Checkpoint Blockade in Melanoma and Triple-Negative Breast Cancer.
Zhang Z; Richmond A; Yan C
Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806358
[TBL] [Abstract][Full Text] [Related]
20. PI3K/Akt/mTOR inhibitors in breast cancer.
Lee JJ; Loh K; Yap YS
Cancer Biol Med; 2015 Dec; 12(4):342-54. PubMed ID: 26779371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]